Skip to main content

Aggregator

Development of a brain-penetrant G9a methylase inhibitor to target Alzheimer's disease-associated proteopathology

10 months 1 week ago
Current Aβ-targeting therapeutics for Alzheimer's disease (AD) only slow cognitive decline due to poor understanding of AD pathogenesis. Here we describe a mechanism of AD pathogenesis in which the histone methyltransferase G9a noncanonically regulates translation of hippocampal proteins associated with AD pathology. Correspondingly, we developed a brain-penetrant inhibitor of G9a, MS1262, which restored both age-related learning & memory and noncognitive functions in multiple AD mouse models....
Ling Xie

Revealing the location and dynamics of a concealed binding site in the dopamine transporter

10 months 1 week ago
The dopamine transporter (DAT) is linked to neuropsychiatric disorders including ADHD, Parkinson's disease, and substance use disorders. Accordingly, DAT is the target of illicit drugs and clinically important medicines. However, the number and function of ligand binding sites in DAT is enigmatic due to conflicting data from available structures and molecular pharmacology. Herein, we design force sensors with DAT ligands and measure their interaction forces with wild-type and mutated DATs, from...
Rong Zhu

Phylogenetic divergence of GABA<sub>B</sub> receptor signaling in neocortical networks over adult life

10 months 1 week ago
Cortical circuit activity is controlled by GABA-mediated inhibition in a spatiotemporally restricted manner. GABA(B) receptor (GABA(B)R) signalling exerts powerful slow inhibition that controls synaptic, dendritic and neuronal activity. But, how GABA(B)Rs contribute to circuit-level inhibition over the lifespan of rodents and humans is poorly understood. In this study, we quantitatively determined the functional contribution of GABA(B)R signalling to pre- and postsynaptic domains in rat and...
Max A Wilson